Table 5.
Renal cell carcinoma studies n (%)
| Author | Type of microsphere | Type of mets (patients) | Response criteria | Response | Median OS |
| (publish date and study type) | (average dosage or activity) | @ 1st assessment | |||
| Abdelmaksoud et al[30] | SIR-Spheres | RCC (6) | mRECIST | 3 CR (60) | 12 mo |
| (3/2012, RS) | (median 1.89 Gbq) | @ 25 mo (mean) | 1 PR (20) | ||
| 1 PD (20) | |||||
| 1 lost | |||||
| Hamoui et al[38] | Therasphere | RCC (1) | Unspecified | 1 (100) SD | Patient died 23 mo after SIRT |
| (2/2013, case report) | (80 Gy) | @ 1.8 mo |
SIRT: Selective internal radiation therapy; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival.